New steroids and new salicylates in inflammatory bowel disease: a critical appraisal.
Although new salicylates are now available for the treatment of ulcerative colitis, sulphasazaline still has an important therapeutic role. The role of salicylates in Crohn's disease is limited to the mild activity phase; further data are required to clarify its role in maintenance on remission. New steroids are a real alternative to traditional steroids in active ulcerative colitis and Crohn's disease.
Campieri
M
M
Centre for inflammatory Bowel Disease, Department of Internal Medicine, University of Bologna, Italy. campieri@med.unibo.it
D000208:Acute Disease; D001241:Aspirin / Q000627:therapeutic use; D001507:Beclomethasone / Q000627:therapeutic use; D019819:Budesonide / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012459:Salicylates / Q000627:therapeutic use*; D012460:Sulfasalazine / Q000627:therapeutic use
D005938:Glucocorticoids; D012459:Salicylates; D012460:Sulfasalazine; D019819:Budesonide; D011239:Prednisolone; D001507:Beclomethasone; D001241:Aspirin